EyePoint Pharmaceuticals, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:EYPT
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 803 out of 851
Universe
Global Universe 13755 out of 15100
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Boryung Corp. |
33.5
High
|
605 out of 851 |
Phathom Pharmaceuticals, Inc. |
33.8
High
|
615 out of 851 |
Hikal Ltd. |
37.4
High
|
760 out of 851 |
IGM Biosciences, Inc. |
39
High
|
801 out of 851 |
EyePoint Pharmaceuticals, Inc. |
39.1
High
|
803 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
EyePoint Pharmaceuticals, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
EyePoint Pharmaceuticals, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted EyePoint Pharmaceuticals, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level